Walder Wyss and VISCHER: Boehringer acquires T3 Pharma
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap forward in the field of cancer treatment.
T3 Pharma boasts a cutting-edge therapy platform utilizing live bacteria to deliver immune-modulating proteins directly to cancer cells and tumor micro-environments. Recognizing the need for enhanced long-term remission rates, Boehringer Ingelheim plans to revolutionize cancer treatment by integrating T3 Pharma’s pioneering technology into its arsenal of immuno-oncology platforms.
With the guidance of Walder Wyss, Boehringer Ingelheim’s strategic move is poised to reshape the landscape of cancer treatment, reinforcing the company’s commitment to advancing oncology solutions and making a positive impact on the lives of those affected by cancer. The team was led by partner Alexander Gutmans (pictured left) and associate Lucas Maurer (pictured right), played a pivotal role in facilitating this groundbreaking acquisition. The expert team provided invaluable legal counsel, ensuring a seamless transition in this transformative venture and was composed by Robert von Rosen (partner, corporate/M&A), Janine Corti (counsel, tax), Michelle Bruni (managing associate, tax), Natascha Rizzi (associate, tax), Benjamin Suter (counsel, commercial contracts), Simon Olstein (associate, corporate/M&A and venture capital, commercial contracts), Christoph Burckhardt (associate, corporate/M&A and venture capital), Yannick A. Moser (managing associate, employment) and Dario Glauser (associate, employment).
VISCHER advised the sellers of T3 Pharmaceuticals on all legal aspects related to the transaction. The team was led by partner Christian Wyss (corporate/M&A, pictured) with Nadia Tarolli (partner, tax), Luzius Zumstein (managing associate, corporate/M&A), Nora Heuberger (managing associate, tax), Adrian Briner (managing associate, tax), Lukas Wendt (associate, corporate/M&A), Alessandro Meyer (associate, corporate/M&A), Sonja Dätwyler (junior associate, corporate/M&A), and Sophie Zimmermann (junior associate, corporate/M&A).
